

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

TEVA PHARMACEUTICALS USA, INC.,  
*Petitioner*

v.

CORCEPT THERAPEUTICS, INC.,  
*Patent Owner*

---

Case PGR2019-00048  
U.S. Patent No. 10,195,214

---

**DECLARATION OF TY CARROLL, M.D.**

## TABLE OF CONTENTS

I.	INTRODUCTION .....	1
II.	EXPERIENCE AND QUALIFICATIONS.....	2
III.	SUMMARY OF OPINIONS.....	3
IV.	BACKGROUND .....	4
	A.    Cushing’s syndrome .....	4
	B.    Korlym® .....	5
	C.    Drug-Drug Interactions .....	7
	D.    My Practices for Treatment of Cushing’s Syndrome.....	9
V.	LEGAL STANDARDS .....	10
VI.	THE CLAIMS OF THE ’214 PATENT WOULD NOT HAVE BEEN OBVIOUS.....	12
	A.    The POSA.....	12
	B.    Dr. Greenblatt’s Cited References .....	14
	1.    The Korlym® Label.....	14
	2.    Lee.....	18
	3.    FDA Guidance .....	21
	C.    A POSA Would Not Have Reasonably Expected To Be Able To Safely And Effectively Administer A Daily Dose Of 600 mg Of Mifepristone In Combination With A Strong CYP3A Inhibitor .....	22
	1.    A POSA Would Not Have Prescribed More Than 300 mg Mifepristone In Combination With A Strong CYP3A Inhibitor .....	23
	2.    I Disagree With Dr. Greenblatt’s Opinions Regarding How A POSA Would Have Understood The Korlym Label And Lee, With Or Without The FDA Guidance.....	31
VII.	CONCLUSION.....	42

I, Ty Carroll, hereby declare and state as follows:

I submit this declaration on behalf of Corcept Therapeutics, Inc. (“Corcept”), the owner of U.S. Patent No. 10,195,214, (“the ’214 patent”) in connection with the Petition for Post-Grant Review filed by Teva Pharmaceuticals USA, Inc. (“Teva” or “Petitioner”).

I. **INTRODUCTION**

1. In this report, I have been asked to respond to certain opinions in the Declaration of Dr. David J. Greenblatt, M.D. (“Greenblatt Declaration”) regarding the alleged invalidity of the ’214 patent that was submitted on behalf of Petitioner, as well as to provide my own understanding of the state of the relevant art at the time of the invention claimed in the ’214 patent.

2. I am being compensated for my time at my usual rate of \$500 per hour. My compensation does not depend in any way on the substance of my testimony or the outcome of this or any other case.

3. I expressly reserve the right to supplement the opinions expressed herein, as well as the bases for my opinions, in response to additional expert declarations submitted by Teva, or any additional discovery or other information provided in this matter.

## II. EXPERIENCE AND QUALIFICATIONS

4. I have been a practicing endocrinologist for over 11 years. As a practicing endocrinologist, I spend the vast majority of my time seeing patients, including individuals with Cushing's syndrome. I have treated patients with Cushing's syndrome with mifepristone for at least the last four years.

5. I am also an assistant clinical professor in the Endocrinology Center and Clinics at the Medical College of Wisconsin. I am currently teaching the second year medical student adrenal disease physiology course.

6. I received a B.S. in Biochemistry from the University of Wisconsin in 1998. I then obtained my M.D. from the Medical College of Wisconsin in 2002. Following that, I did my residency in Internal Medicine at the Medical College of Wisconsin and Affiliated Hospitals from 2002-2005. I then completed a fellowship in Endocrinology, Metabolism, and Clinical Nutrition at the Medical College of Wisconsin and Affiliated Hospitals from 2006-2008. I am Board certified by the American Board of Internal Medicine in Endocrinology.

7. During my career I have received numerous honors and awards, including M-Magazine Top Doctors-Endocrinology (2012-2020), "Best Doctors" in America (2013-2018), and the Medical Student Teacher Award (2009).

8. I have served as a reviewer for a number of peer reviewed journals, including European Journal of Endocrinology, Postgraduate Medical Journal,

Clinical Endocrinology, Endocrine Practice, Journal of the American Board of Family Medicine, Endocrinology, and Journal of Clinical Endocrinology and Metabolism.

9. A copy of my curriculum vitae, including a list of publications I have authored, is attached to this declaration as Appendix A.

### III. SUMMARY OF OPINIONS

10. I have reviewed the '214 patent, the Greenblatt Declaration, and other materials cited herein. I have been asked by counsel to use March 1, 2017 as the date of invention for the '214 patent claims. It is my opinion that Dr. Greenblatt has failed to establish that any claim of the '214 patent would have been obvious over the cited references and/or general knowledge in the field, at the time of the '214 patent's invention.

11. Specifically, it is my opinion that as of March 2017, a person of ordinary skill in the art ("POSA") would not have had a reasonable expectation of being able to successfully perform the methods claimed in the '214 patent. A POSA would not have reasonably expected that 600 mg of mifepristone daily could be co-administered with a strong CYP3A inhibitor safely and effectively to patients with Cushing's syndrome. Instead, at that time the POSA would have expected that it would not be safe to administer more than 300 mg of daily

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.